At #ASH23, @Eddie_Cliff (@BrighamWomens) shared insights from the POLARIX trial, revealing differences in the efficacy of R-CHP between subgroups of patients with #DLBCL.

Watch here:

👉

#Lymphoma #LYsm #TrialUpdate #CTSM #HemOnc @ASH_Hematology

POLARIX: R-CHP is more effective in the subgroup of DLBCL patients with activated B-cell origin

Edward Cliff, MPH, MBBS, Brigham and Women’s Hospital, Boston, MA, speaks on the POLARIX trial (NCT03274492), focusi...

ow.ly

Want to hear about the highlights in the field of CLL from #ASH23, with a focus on the FLAIR study?

Then check out our interview with @DrMDavids of @DanaFarber here:

👉

#CLLsm #LeuSM #Leukemia #CTSM #HemOnc #ASH23 @ASH_hematology

CLL highlights from ASH 2023: the FLAIR study

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the highlights in the space of chronic lym...

ow.ly

🎥 @thomas_cluzeau of @CHUdeNice talks on the preliminary results of the VENTOGRAPH trial of AZA, VEN, and DLI in MDS and AML following AHSCT relapse.

Watch here:

👉

#MDSsm #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc #ASH23 @ASH_hematology

VENTOGRAPH trial: AZA, VEN, and DLI in patients with MDS and AML who have relapsed following AHSCT

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the preliminary findings of the ...

ow.ly

Prof. John Gribben (@QMBCI) gave a wonderful insight into axi-cel in R/R #FollicularLymphoma at #ASH23 with an updated comparison of ZUMA-5 and SCHOLAR-5.

Watch here:

👉

#LYMsm #Lymphoma #NonHodgkinLymphoma #ImmunoOnc #HemOnc @ASH_hematology

Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort

John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, comments on the updated 4-year ...

ow.ly